falsefalse

Evolving Treatments in Hepatocellular Carcinoma: Updates from ASCO GI 2024 - Episode 6

IMBrave-050 Study Overview

Dr Shroff breaks down the combination of atezolizumab and bevacizumab as outlined by the IMBrave-050 study.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Hepatocellular Carcinoma (HCC) Disease State Overview
    EP. 2: Utilizing Interventional Radiology and Liver-directed Therapies
    EP. 3: Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC
    EP. 4: EMERALD-1 Study: Significance as Presented at ASCO GI 2024
    EP. 5: EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies
    Now Viewing
    EP. 6: IMBrave-050 Study Overview
    EP. 7: Patient Profile 1: Advanced HCC Treated with Durvalumab and Tremelimumab
    EP. 8: HIMALAYA Study in Advanced Stage HCC
    EP. 9: Establishing Optimal HCC Treatment Strategy
    EP. 10: IMBrave150 Study Overview
    EP. 11: HCC Treatment Strategy Driven by Real-World Evidence
    EP. 12: Combining Liver-directed and Systemic Therapies in HCC
    EP. 13: Patient Profile 2: Patient Progression After Frontline HCC Therapy
    EP. 14: CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape
    EP. 15: REGONEXT Study: Driving Second-line HCC Treatment Strategy
    EP. 16: Trajectory of Evolving HCC Treatment Landscape

    Related Content:

    OncLive Peer Exchange® Hepatocellular CarcinomaGastrointestinal Cancer
    Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study
    Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
    Giants of Cancer Care® Announces the 13th Annual Class of Inductees
    x